Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

IIImmunic, Inc.

35 indications, side-by-side phase, drug & LoA

$13.86

+0.79 (+6.04%)

C 56Pipeline Score Undervalued Pharma · Clinical
Market Cap
177.76 M
EPS
-6.03
P/E Ratio
-
Value Trade
3.64 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    25.63 M

  • Operating CF

    -17.30 M

  • Total Assets

    189.74 M

  • Total Liabilities

    38.51 M

  • Equity

    151.23 M

  • D/E Ratio

    12,345

5.58 %
Week
45 %
1 Month
37.37 %
3 Month
91.63 %
6 Month
-90.28 %
5 Year
-99.73 %
All Time
Cash Data
Healthy

  • Cash Position

    186.63 M

  • Monthly Burn

    5.77 M

  • Runway

    31.5 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 13, 2026
Overview
Volume
195.63 K
52 Week Range
5.06 - 15.10
% held by Insiders
0.97 %
% held by Institutions
68.32 %
Enterprise Value
-8.45 M
Total Shares
136.25 M
Short %
1.46 %
Float Shares
120.71 M
Company Description
HQ: 1200 AVENUE OF THE AMERICAS, N...
Employees:95
https://www.imux.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 Readout example
Vidofludimus Calcium (IMU-838) relapsing multiple sclerosis
Phase 3
—
Small Molecules
Nervous System
Vidofludimus Calcium (IMU-838) relapsing multiple sclerosis
Phase 3
—
Small Molecules
Nervous System
Vidofludimus Calcium (IMU-838) relapsing multiple sclerosis
Phase 3
—
Small Molecules
Nervous System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C56
Pipeline Score
$1.2B
Pipeline Value
Undervalued
Valuation Signal
1
Drugs Scored
6.6x
rNPV / MCap
Top 82%
Micro Cap
(rank 164 of 905)
Percentile Rank
Immunic, Inc. carries a moderate pipeline score (56/100), with $4.7B risk-adjusted pipeline value, led by IMU-838 in Multiple Sclerosis (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IMU-838
Small molecule		Multiple SclerosisPhase 3NCT0513444164% $4.7B ACTIVE NOT_RECRUITING 1,121 FAST B (77) Sep 1, 2033MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Vidofludimus Calcium
Relapsing-Remitting Multiple Sclerosis
Phase 2
2025-06-24
Vidofludimus Calcium
Relapsing-Remitting Multiple Sclerosis
Phase 2
2025-06-24
Vidofludimus Calcium
Relapsing-Remitting Multiple Sclerosis
Phase 2
2025-06-24
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in IMUX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IMUX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMUX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMUX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
IMUX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
IMUX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Immunic, Inc. (IMUX) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How IMUX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Multiple Sclerosis #7 of 20 PHASE 3 IMU-838
SNY NVS BIIB
$31.92B 0.89 CONTENDER